OncologyOnline.net

Oncology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Onco News

Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) was shown to improve overall survival ( OS ) and durability of response versus chemotherapy in first line ( 1L ) advanced non-small cell lung cancer ( NSCL ...


KEYNOTE-177 is a phase 3, randomized open-label study evaluating the efficacy and safety of Pembrolizumab ( Keytruda ) versus standard of care chemotherapy ± Bevacizumab ( Avastin ) or Cetuximab ( Erb ...


Treatment with checkpoint inhibitors or targeted therapy improves outcomes in patients with BRAF V600–mutant advanced melanoma; however, many patients subsequently progress and die. Preliminary evide ...


Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men with nonmetastatic castration-resistant prostate cancer ( nmCR ...


In the phase 3 CheckMate 227 Part 1 ( minimum follow-up, 29.3 months ), first line 1L Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) has significantly improved overall survival ( OS ) versus chemotherap ...


This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced melanoma. At the 3-year follow-up, the combination ( combo ) of Talimog ...


Selpercatinib ( Retevmo ) is a highly selective and potent small molecule RET kinase inhibitor. Researchers have reported an update on the efficacy and safety of Selpercatinib in RET-fusion+ non-smal ...


Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...


Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on demonstrated benefits on progression-free survival ( PFS ) and overall survival ( OS ). To bett ...


First-line immunotherapy with / without chemotherapy is standard of care for patients with advanced non-small-cell lung cancer ( NSCLC ); however, there is a need for effective treatment options after ...


Approximately, 95% of patients who have an initial response to ALK tyrosine kinase inhibitors ( ALK-TKIs ) exhibit an incomplete response resulting in residual disease that enables the emergence of ac ...


Pembrolizumab ( Keytruda ) monotherapy has shown promising antitumor activity and manageable safety in patients with metastatic triple-negative breast cancer ( TNBC ) in KEYNOTE-012, -086 and -119. ...


Tivozanib ( Fotivda ) is a potent and highly selective VEGFR inhibitor. TIVO-3 is a phase 3 study designed to compare the efficacy and safety of Tivozanib with those of Sorafenib ( Nexavar ) as 3rd an ...


Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major challenge. Tomivosertib, a potent and highly selec ...


Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous system ( CNS ) and overcome resistance to 2nd-generation ( 2nd-gen ) ALK TK ...